On March 13, 2024 Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, reported that preclinical data from its oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 held in San Diego, CA (Press release, Affini-T Therapeutics, MAR 13, 2024, View Source [SID1234641131]). In addition, two trial-in-progress posters for Affini-T’s Phase 1 clinical-stage programs targeting KRAS G12V, the company-sponsored AFNT-211 study and the Fred Hutchinson Cancer Center investigator-initiated AFNT-111 study, will be presented at the same conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details are as follows:

Title: Non-viral engineered T cell therapy specific for the hotspot mutation p53 R175H that integrates signal 1 (TCR), signal 2 (co-stimulation) and signal 3 (cytokine) and co-opts FasL-dependent apoptosis to achieve a coordinated antitumor CD4/8 T cell response
Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Abstract Number: 7242
Presenting Author: Gary Shapiro, Ph.D., VP Biology Discovery, Affini-T Therapeutics
Date/Time: Sunday, April 7, 2024, 1:30 PM – 5:00 PM

Title: AFNT-212: A TRAC-knocked-in KRAS G12D-specific TCR-T cell product enhanced with CD8αβ and a chimeric cytokine receptor for treatment of solid cancers
Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Abstract Number: 5973
Presenting Author: Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics
Date/Time: Sunday, April 7, 2024, 1:30 PM – 5:00 PM

Title: Identifying novel patient-derived T cell receptors targeting TP53 public neoantigens
Session: Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T
Abstract Number: 441
Presenting Author: Michael V. Gormally, M.D., Ph.D., Fellow, Memorial Sloan Kettering Cancer Center
Date/Time: Sunday, April 7, 2024, 1:30 PM – 5:00 PM

Title: AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR; CD8α/β coreceptor; and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
Session: Phase I Clinical Trials in Progress 1
Abstract Number: CT076
Presenting Author: Dirk Nagorsen, M.D., Chief Medical Officer, Affini-T Therapeutics
Date/Time: Monday, April 8, 2024, 9:00 AM – 12:30 PM

Title: Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high-affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations
Session: Phase I Clinical Trials in Progress 1
Abstract Number: CT082
Presenting Author: Aude G. Chapuis, M.D., Fred Hutchinson Cancer Center
Date/Time: Monday, April 8, 2024, 9:00 AM – 12:30 PM

About Affini-T Therapeutics